Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial

• Published in: Journal of international medical research Vol. 48; no. 6; p. 300060520931323
• Main Authors: Kim, Hyun-Sook, Choi, Won-Ho, Kim, Bo Young, Kim, Sung Soo, Lee, Sang-Il, Kim, Sang-Hyon, Choi, Sung Jae, Kim, Geun-Tae, Hur, Jin-Wuk, Lee, Myeung-Su, Kim, Yun Sung, Hong, Seung-Jae
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.06.2020; Sage Publications Ltd; SAGE Publishing
• Subjects: Arthritis, Rheumatoid - drug therapy; Celecoxib - adverse effects; Clinical trials; Cyclooxygenase 2 Inhibitors - adverse effects; Double-Blind Method; Double-blind studies; Humans; Prospective Clinical Research Report; Pyrazoles - adverse effects; Rheumatoid arthritis; Sulfonamides - therapeutic use; Treatment Outcome; renal toxicity; non-inferiority; CELEBREX; gastrointestinal toxicity; CELBESTA; rheumatoid arthritis; pain relief; Korea
• ISSN: 0300-0605; 1473-2300; 1473-2300
• DOI: 10.1177/0300060520931323

Objectives Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA). CELBESTA® is a generic equivalent to CELEBREX®, a celecoxib preparation. This study compared the efficacy and safety of CELBESTA® and CELEBREX® in patients with RA. Methods This was a multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority clinical trial. The primary endpoint was a change from baseline in self-assessed pain intensity determined using a 100-mm visual analog scale after 6 weeks of treatment. Results After a washout period, 119 eligible subjects were randomized to one of two groups (CELBESTA® group, n = 61; CELEBREX® group, n = 58). CELBESTA® was not inferior to CELEBREX® because the upper limit of two-sided 95% confidence interval (CI) for the difference between the two groups (difference in the least square [LS] mean, −8.68 mm; two-sided 95% CI −16.59 mm to −0.77 mm) was less than the non-inferiority margin (10 mm). There were no significant differences in GI complications and renal toxicity. Conclusions CELBESTA® was not inferior to CELEBREX® with regard to the pain relief efficacy in RA patients, and the tolerability and safety profiles were excellent and at similar levels for both preparations.